Skip to main content
. 2013 Feb 28;108(5):1061–1070. doi: 10.1038/bjc.2013.74

Figure 5.

Figure 5

Patient overall survival as of 4 December 2012. Survival of each patient was measured from the date the first dose of p28 was administered until death from any cause or last follow-up. M=melanoma, C=colon, P=prostate, S=sarcoma and Pa=pancreatic cancer. *Alive (green bars). CR=complete response, PR=partial response, SD=stable and PD=progressive disease. Median overall survival: 28 weeks. Range alive: 110–158 weeks, median 140 weeks. Range of date of death (DOD) for deceased patients: 7–71 weeks, Median 19 weeks. Values within each bar represent the dose level (range) each patient received. #, progressive disease 28 December 2011. ‡, Cancer recurrence 23 July 2012.